Kidney Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Pharmacologic Class, By Country, And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology
                     1.1. Information procurement
                     1.2. Information or Data Analysis
                         1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                     3.1. Disease Primer
                     3.2. Epidemiology
Chapter 4 Global Market Overview
                     4.1 Market by Therapeutic Class
                     4.2 Market Size and Forecast 2016 - 2022
                     4.3 Market Share Distribution, by Company 2016 - 2022
                     4.4 Sales Performance, by Pharmacologic Class
                     4.5 Market Dynamics and Brand Strategies
                     4.6 Patent Expiry Analysis
                     4.7 Kidney Cancer Drugs Market: Drivers and Restraints
                         4.7.1 Drivers
                         4.7.2 Challenges
                     4.8 M&A, Deal Landscape (2013 - 2017 YTD)
                         4.8.1 Mergers & Acquisitions
                         4.8.2 Deals Landscape
                     4.9 Evolution of Biosimilars
                     4.10 Emerging Markets
                     4.11 Reimbursement Scenario
                     4.12 Kidney Cancer Sector SWOT
Chapter 5 Pipeline Intelligence
                     5.1. Pipeline Landscape
                         5.1.1 Leading Drugs in Development
                         5.1.2 Key R&D Trends
                     5.2 Pipeline Landscape
                         5.2.1 Late Stage Pipeline and Sales Forecast
                         5.2.2 Profiles of Disruptive Drugs
                     5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
                     6.1 Pfizer
                         6.1.1 Company Overview
                         6.1.2 Current Product Portfolio
                         6.1.3 Product Sales Forecast Through 2022
                         6.1.4 Strategic Initiatives
                             6.1.4.1 Key Company News Flow
                             6.1.4.2 Catalysts & Events Calendar
                         6.1.5 Pipeline Analysis & Overview
                         6.1.6 SWOT
                     6.2 Novartis
                         6.2.1 Company Overview
                         6.2.2 Current Product Portfolio
                         6.2.3 Product Forecast Sales Through 2022
                         6.2.4 Strategic Initiatives
                             6.2.4.1 Key Company News Flow
                         6.2.5 Pipeline Analysis & Overview
                         6.2.6 SWOT
                     6.3 Bayer
                         6.3.1 Company Overview
                         6.3.2 Current Product Portfolio
                         6.3.3 Product Forecast Sales Through 2022
                         6.3.4 Strategic Initiatives
                             6.3.4.1 Key Company News Flow
                         6.3.5 Pipeline Analysis & Overview
                         6.3.6 SWOT
                     6.4 Genentech
                         6.4.1 Company Overview
                         6.4.2 Current Product Portfolio
                         6.4.3 Product Forecast Sales Through 2022
                         6.4.4 Strategic Initiatives
                             6.4.4.1 Key Company News Flow
                             6.4.4.2 Catalysts & Events Calendar
                         6.4.5 Pipeline Analysis & Overview
                         6.4.6 SWOT
                     6.5 Bristol-Myers Squibb
                         6.5.1 Company Overview
                         6.5.2 Current Product Portfolio
                         6.5.3 Product Forecast Sales Through 2022
                         6.5.4 Strategic Initiatives
                             6.5.4.1 Key Company News Flow
                             6.5.4.2 Catalysts & Events Calendar
                         6.5.5 Pipeline Analysis & Overview
                         6.5.6 SWOT
                     6.6 Exelixis
                         6.6.1 Company Overview
                         6.6.2 Current Product Portfolio
                         6.6.3 Product Forecast Sales Through 2022
                         6.6.4 Strategic Initiatives
                             6.6.4.1 Key Company News Flow
                             6.6.4.2 Catalysts & Events Calendar
                         6.6.5 Pipeline Analysis & Overview
                         6.6.6 SWOT
                     6.7 Eisai
                         6.7.1 Company Overview
                         6.7.2 Current Product Portfolio
                         6.7.3 Product Forecast Sales Through 2022
                         6.7.4 Strategic Initiatives
                             6.7.4.1 Key Company News Flow
                         6.7.5 Pipeline Analysis & Overview
                         6.7.6 SWOT
                     6.8 Prometheus Labs
                         6.8.1 Company Overview
                         6.8.2 Current Product Portfolio
                         6.8.3 Product Forecast Sales Through 2022
                         6.8.4 Strategic Initiatives
                             6.8.4.1 Key Company News Flow
                         6.8.5 SWOT
Chapter 7 Market Outlook
                     7.1 What the Future Holds
                     7.2 The Winners and Losers
                         7.2.1 Winners
                         7.2.2 Losers
                     7.3 Emerging Companies & Technology Platforms
                     7.4 The Road Ahead

List of Tables

TABLE 1 Incidence Rate per 100,000 in Seven Major Markets
TABLE 2 Incidence Rate per 100,000 in Forecast, Spain
TABLE 3 Marketed Drugs for Kidney Cancer
TABLE 4 Marketed Drugs for Kidney Cancer
TABLE 5 Sales Performance by Therapeutic Class, 2016 - 22
TABLE 6 Sales Performance by Market, in USD million, 2016 - 22
TABLE 7 Sales Performance by Market, by Pharmacologic Class, 2016 - 22
TABLE 8 Sales Performance by Pharmacologic Class, 2016 - 22
TABLE 9 U.S. Patents for Current Kidney Cancer Drugs
TABLE 10 Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 11 R&D Pipeline Overview
TABLE 12 Late Stage Pipeline
TABLE 13 Bavencio
TABLE 14 Tecentriq
TABLE 15 Fotivda
TABLE 16 Epacadostat
TABLE 17 Rocapuldencel-T
TABLE 18 Pipeline Forecast
TABLE 19 Pfizer Sales Forecast, 2016 - 2022
TABLE 20 Pfizer Pipeline
TABLE 21 Novartis Sales Forecast, 2016 - 2022
TABLE 22 Bayer Sales Forecast, 2016 - 2022
TABLE 23 Bayer Pipeline
TABLE 24 Genentech (Roche) Sales Forecast, 2016 - 2022
TABLE 25 Genentech (Roche) Pipeline
TABLE 26 Bristol-Myers Squibb Sales Forecast, 2016 - 2022
TABLE 27 Bristol-Myers Squibb Pipeline
TABLE 28 Exelixis Sales Forecast, 2016 - 2022
TABLE 29 Exelixis Pipeline
TABLE 30 Eisai Sales Forecast, 2016 - 2022
TABLE 31 Prometheus Labs Sales Forecast, 2016 - 2022

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Race and Gender Specific Prevalence of RCC in the U.S.
FIG. 8 Gender Specific Incidence Rate per 100,000 in the U.K. (1993 - 2014)
FIG. 9 Kidney Cancer Drugs Market Share, by Therapeutic Class, 2016 - 22
FIG. 10 Regional Market Size, 2016 - 2022
FIG. 11 Market Shares Distribution, 2016 - 2022
FIG. 12 Sales by Pharmacologic Class, 2016 - 2022
FIG. 13 Kidney Cancer SWOT
FIG. 14 Pfizer SWOT Analysis
FIG. 15 Novartis SWOT Analysis
FIG. 16 Bayer SWOT Analysis
FIG. 17 Genentech SWOT Analysis
FIG. 18 Bristol-Myers Squibb SWOT Analysis
FIG. 19 Exelixis SWOT Analysis
FIG. 20 Eisai SWOT Analysis
FIG. 21 Prometheus Labs SWOT Analysis